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Objective: To determine the feasibility and acceptability of providing clean birth kits 
(CBKs) containing misoprostol for self-administration in a rural setting in Papua New 
Guinea. 
 
Methods: A prospective intervention study was conducted between April 8, 2013, and 
October 24, 2014. Eligible participants were women in the third trimester of 
pregnancy who attended a prenatal clinic in Unggai Bena. Participants received 
individual instruction and were then given a CBK containing 600 µg misoprostol 
tablets for self-administration following an unsupervised birth if they could 
demonstrate their understanding of correct use of items in the CBK. Data regarding 
the use and acceptability of the CBK and misoprostol were collected during 
postpartum follow-up. 
 
Results: Among 200 participants, 106 (53.0%) had an unsupervised birth, and 99 
(93.4%) of these women used the CBK. All would use the CBK again and would 
recommend it to others. Among these 99 women, misoprostol was self-administered 
by 98 (99.0%), all of whom would take the drug again and would recommend it to 
others. 
 
Conclusion: The findings strengthen the case for community-based use of 
misoprostol to prevent postpartum hemorrhage in remote communities. Large-scale 




Most maternal deaths occur in low-resource settings [1], primarily in remote and rural 
communities when births are not assisted by skilled attendants. Globally, postpartum 
hemorrhage (PPH) is the leading cause of maternal mortality [1], but this 
complication can be prevented by the use of uterotonic agents, such as oxytocin [2]. 
However, oxytocin requires intramuscular administration and refrigerated storage, 
making this potentially life-saving intervention unavailable for the millions of women 
who experience unsupervised delivery. 
 
Misoprostol has been suggested as a substitute to oxytocin in low-resource settings 
[3,4]. The safety and efficacy of 600 µg orally administered misoprostol to prevent 
PPH in community settings has been documented in several countries [3,5–14]. 
Distribution of misoprostol has been undertaken by community health workers, 
including traditional birth attendants [5–8,13]. In some settings, this drug has been 
distributed to women for self-administration [9–12,14]. Such distribution is frequently 
undertaken in conjunction with training and education about birth preparedness, the 
importance of supervised births, recognizing danger signs (including PPH), the 
correct timing for taking misoprostol, and common adverse effects [3,6,8–12,14]. 
 
In 2012, in recognition of the limited evidence to support distribution of self-
administered misoprostol, WHO and the International Federation of Gynecology and 
Obstetrics called for research to evaluate the inclusion of misoprostol in effective, 
locally appropriate, and comprehensive community-based interventions [15]. The 
distribution of clean birth kits (CBKs) to support hygienic birth practices is one such 
intervention that has been frequently used in low-resource settings [16]. The 
potential benefit of including additional items in these kits, such as misoprostol, has 
been suggested [17], although this advice has not been formally evaluated in such 
settings. 
 
Papua New Guinea (PNG) is a low-to-middle-income country in the Asia–Pacific 
region. Access to skilled health care in this country is limited as a result of 
geographic, infrastructure, and logistical challenges. The majority (87%) of the 7.2 
million residents of PNG live in rural areas [18]. Furthermore, PNG has one of the 
highest maternal mortality ratios in the world, with 594–733 maternal deaths per 100 
000 live births [1,19]. Although 78% of women in PNG attend a prenatal clinic at 
least once during their pregnancy, only 44% experience supervised delivery within a 
health facility [20]. Many women give birth in the community, either alone or with a 
female relative to support them. In PNG—as in many low-resource settings—PPH 
and sepsis are the leading causes of maternal mortality [21]. 
 
The aim of the present study was to evaluate the distribution of misoprostol as part 
of a comprehensive community-based strategy to prevent PPH and to describe the 
feasibility and acceptability of CBKs and misoprostol among participants in a remote 
rural setting in PNG. 
 
2. Materials and methods  
A prospective community-based intervention study was conducted between April 8, 
2013, and October 24, 2014. Women in the third trimester of pregnancy (on the 
basis of clinical assessment) who attended a prenatal clinic at government health 
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facilities in Unggai Bena were eligible to participate. The eligibility criteria limited the 
time between receiving the intervention and the estimated delivery date. Exclusion 
criteria were a history of mental illness and age younger than 16 years. Ethical 
approval was provided by the Institutional Review Board of the PNG Institute of 
Medical Research, Goroka; the Medical Research Advisory Committee, PNG 
National Department of Health, Port Moresby; and the Human Research Ethics 
Committee, University of Queensland, Brisbane, QLD, Australia. Women willing to 
participate completed written informed consent procedures. For women unable to 
sign owing to illiteracy, a witness signature confirmed that the participant had 
understood the consent process and was providing informed consent. All women 
were assigned a unique study identity number.  
 
The study was conducted within Unggai Bena, one of eight administrative districts in 
the Eastern Highlands Province of PNG. Coverage of maternal health care in this 
predominantly rural area is low, with only 68% of women attending a prenatal clinic 
on at least one occasion; the supervised birth rate is just 38% [20]. The present 
study site of Upper Bena is accessible by one unsurfaced road, often impassable 
after heavy rain. Many villages are located in steep mountainous terrain and 
accessible only by bush tracks. Four government health facilities in the area (three 
aid posts and one health center) offer a range of preventive and curative services, 
including weekly prenatal clinics. The health center is equipped to manage 
uncomplicated births, which are conducted primarily by nurses. There is one midwife 
at the health center. 
 
Review of the available provincial-level maternal health data for 2012 (the year in 
which the present study was planned) indicated a supervised birth rate at the study 
site of approximately 7%. The proportion of women who attend the provincial 
hospital, or other facilities, for a supervised birth is not systematically recorded; 
however, previous research in the area suggested that most women give birth 
unsupervised in the community, either alone or supported by family [19,22]. 
 
Visual teaching aids were designed using nationally available safe motherhood 
teaching aids and messages, and piloted by a research team from the PNG Institute 
of Medical Research, Goroka. The research team comprised a health extension 
officer (E.W.) (a professional health worker with 4 years of formal training), a midwife 
(P.H.), and two community liaison officers (M.M. and M.T.), supported by the 
principal investigator (L.M.V.). All team members were experienced in the conduct of 
community-based field research. The teaching aids, which highlighted key messages 
relating to birth preparedness (Box 1), were used to disseminate information through 
community sessions at both informal and formal gatherings, including at village 
markets, after church services, and at participating prenatal clinics. 
 
Pictorial flipcharts for the CBKs and misoprostol, including correct use of each item, 
were also designed and piloted. Each CBK contained a piece of soap, a pair of 
gloves (non-sterile), a plastic sheet, a scalpel blade, two cord ties, and a sealed 
packet containing three misoprostol tablets (600 µg in total) to be taken orally after 
delivery. The misoprostol tablets were repackaged by the research team and labeled 
“safer afterbirth” tablets before inclusion in the CBK to comply with a requirement 
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from the ethics committees in PNG following concerns that misoprostol could be 
used inappropriately (e.g. to induce abortion). 
 
At enrollment, women received one-to-one education using the pictorial flip charts, 
before being provided with the CBK. Educational activities were undertaken by the 
health extension officer or research midwife. Women were advised about the risks of 
taking the misoprostol tablets too soon (i.e. before delivery) and about common 
minor adverse effects. Using a study-specific checklist, participants were required to 
demonstrate their understanding of the correct use of each item in the CBK, 
specifically the use of misoprostol, before the CBK was provided. Women who did 
not demonstrate the correct knowledge did not receive the CBK at enrollment. These 
women were asked to return to the prenatal clinic the following week to receive 
further instruction and to be reassessed regarding their knowledge before provision 
of the CBK. A pictorial insert on the use of each item (Figure 1) and a birth 
notification card (to enable postpartum follow-up) were also included in the CBK. 
 
Sociodemographic data and obstetric history were collected using a study-specific 
case record form that had previously been tested in this setting (unpublished data). 
Locator information, including distance from health facility and road access, was 
collected to enable the research team to visit participants in their villages, 
communicate key messages to their community (Box 1), and to facilitate postnatal 
follow-up. 
 
Participants were visited in the community by the research team during the 
postpartum period. A semi-structured questionnaire was used to collect information 
relating to birth experience (including location of birth) and the use of each item in 
the CBK. Probing questions were used where necessary. Unused CBKs, including 
misoprostol tablets, were collected by the research team and disposed of in 
accordance with study-specific standard operating procedures. 
 
All individual prenatal information sessions and postpartum interviews took place in 
quiet, private areas at the health facility or in the woman’s home, unless she 
requested otherwise. All community information sessions and individual interviews 
were conducted in Tok Pisin, one of three official national languages in PNG. 
 
The data were analyzed using STATA version 10.0 (StataCorp, College Station, TX, 
USA). All women enrolled in the study were included in the analysis irrespective of 
whether they received the CBK. Data were summarized as frequencies and 
percentages. Bivariate analysis and the χ2 test were performed to identify 
associations between unsupervised versus supervised births, sociodemographic and 
obstetric history, and use of CBK and misoprostol. The Fisher exact test was used to 
compare differences in proportions when small numbers were recorded. P<0.05 was 
considered statistically significant. 
 
3. Results 
A total of 200 women were recruited and underwent postpartum follow-up (Figure 2). 
A CBK was given to 195 (97.5%) women; 5 (2.5%) were unable to demonstrate 
knowledge of the safe use of the CBK items at enrollment and did not return to the 
prenatal clinic as requested before giving birth, so they were not issued with a CBK. 
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Every village from which a woman was enrolled was visited at least once by the 
research team to disseminate the key messages (Box 1). 
 
Location of birth and sociodemographic characteristics are outlined in Table 1. 
Unsupervised births were recorded among 106 (53.0%) participants, of whom 43 
(40.6%) either chose to give birth in the community or were told to give birth there by 
their husbands (data not shown). Compared with women who had a supervised birth, 
women who experienced unsupervised birth were more likely to have no or limited 
formal education (P=0.017) and to be married (P=0.037) (Table 1). No statistically 
significant between-group differences were found for age, employment status, or 
religious denomination. 
 
Women giving birth for the first time were more likely to have a supervised birth than 
were multiparous women (P=0.002) (Table 2). No maternal deaths occurred among 
the study participants. Two infants were stillborn; both were supervised births. 
 
Overall, all or part of the CBK was used by 115 (59.0%) of the 195 who received 
one. Among all 106 women who had an unsupervised birth, most used the CBK 
(Table 3). Two (1.9%) of the 106 women who had an unsupervised birth did not use 
the CBK because they did not have it with them at the onset of labor. The other five 
women who had unsupervised births and did not use the CBK had not been given 
one. 
 
All items were employed as instructed among the majority of the 115 women who 
used their CBK (Table 3). Of the 99 women who gave birth unsupervised and used 
the CBK, all but one used the scalpel blade to cut the umbilical cord (Table 3). The 
one exception used scissors, stating that she had forgotten that the scalpel was 
provided. Among the 16 women who had a supervised birth and used the CBK, the 
most frequently used items were the gloves and clean plastic sheet (Table 3). 
 
Among the 115 women who used their CBK, 112 (97.4%) self-administered the 
misoprostol. Among these, 89 (79.5%) women correctly took the misoprostol 
immediately following the birth of the infant; 18 (16.0%) took their misoprostol after 
expulsion of the placenta; and three women (2.6%) took it later than instructed. Two 
women did not state when it was taken (Table 3). Among those who did not use the 
misoprostol, one woman stated that she did not take it, as she felt she was not 
bleeding “too much”. 
 
Responses to questions relating to acceptability suggested that the majority of 
women who used a CBK would use it again and recommend its use to others (Table 
3). Additionally, almost all the women who self-administered misoprostol said that 
they would take it again and that they would recommend it to other women in their 
community (Table 3). 
 
All 200 women were asked about problems experienced after delivery, specifically 
regarding six symptoms associated with the use of misoprostol (shivering, fever, 
nausea, dizziness, vomiting, and diarrhea). Overall, 164 (82.0%) of the 200 
participants reported at least one symptom after delivery, with shivering the most 
frequently reported event (Table 4). No significant differences in shivering, nausea, 
or dizziness were reported among women who took misoprostol versus those who 
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did not. None of the women reported vomiting or diarrhea. Excessive bleeding after 
delivery (defined as more than two cups of blood) was reported more frequently by 
women who did not take misoprostol than by women who did take this drug 
(P<0.001) (Table 4). 
 
4. Discussion 
The present study demonstrated that a CBK containing misoprostol for self-
administration to prevent PPH was acceptable, feasible, and appropriately used in a 
remote low-resource rural setting. High acceptability and adherence of self-
administered misoprostol have previously been reported in other settings 
[9,11,13,14], but to our knowledge, the present study represents the first time a 
package of interventions, including community-based birth preparedness education 
and the addition of misoprostol within CBKs, has been evaluated in a rural low-
resource context. Additionally, the present study identified a few women who found 
the CBK and misoprostol both useful and acceptable when attending a health facility 
for a supervised birth. These women, who were uncertain that they had received 
injectable oxytocin and were afraid of bleeding, self-administered their misoprostol. 
Whether they informed their care providers at the health facility was unknown. 
 
Through providing communities and women attending prenatal clinics with key 
messages relating to birth preparedness, the present study sought to encourage 
women to undergo supervised births while also providing them with an intervention 
to promote hygienic and safe delivery should they experience an unsupervised birth. 
Constraints on the available data precluded estimates of change in coverage of 
supervised births at a health facility; however, review of provincial-level data and 
health facility records by the present study team for the period 2012–2014 indicated 
a steady increase in new attenders for prenatal care and supervised births in the 
present study area. This increase could reflect the present study intervention; an 
earlier pregnancy study conducted in the same area by the present study team; or 
external factors. Most importantly, the intervention did not lead to an increase in 
unsupervised home births, which had been a concern among some stakeholders. 
 
More than half the women in the present study underwent unsupervised birth in their 
village owing to difficulties with transport, distance, and decision making, a finding in 
line with previous research in the same location [22] and elsewhere [23]. While 
women continue to give birth unsupervised—either through choice or 
circumstances—they remain at risk. The present study highlights the importance of 
using prenatal clinic visits to provide women with birth preparedness messages, 
including promotion of supervised births, and to make CBKs available for those who, 
despite this encouragement, will undergo unsupervised births because of the 
sociocultural and structural constraints within which they live. 
 
Misoprostol is currently available for use in health centers and hospitals throughout 
PNG. The present study demonstrated the potential use of misoprostol when 
combined as a package with other community-based interventions. Several 
safeguards were included to ensure the misoprostol was used as intended. First, the 
present study enrolled only women in late pregnancy—as others have done [14]—to 
reduce the chance that misoprostol was misused in early pregnancy. Second, the 
misoprostol provided in the intervention was re-labeled and packaged with a very 
specific indication. Finally, the CBKs and misoprostol were only distributed to women 
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who could correctly recall key messages on usage. This last safeguard did result in 
five women undergoing unsupervised birth in the community without a CBK. 
Fortunately, all these women had a safe outcome; however, this finding does 
illustrate the balance of risks involved in imposing such safeguards. Packing the 
misoprostol within the CBK also helped ensure the safe storage and management of 
the tablets. The postnatal follow-up visits enabled collection of any unused 
misoprostol tablets, thereby minimizing the risk of inappropriate use. 
 
Although there is limited evidence that the use of CBKs reduces maternal sepsis 
[17], earlier work in PNG highlighted that many women give birth in extremely 
unclean circumstances (e.g. in coffee gardens or on riverbanks) [22,24]. Hence, 
promoting clean and hygienic births in this setting was considered a priority. 
 
The present study was not designed to evaluate the effectiveness of misoprostol for 
the prevention of PPH. Nevertheless, the women who took this drug were 
substantially less likely to report excessive bleeding than were those who did not 
take it. 
 
Several limitations of the present study should be considered. Through only enrolling 
at prenatal clinics in the last trimester of pregnancy, the opportunity was missed to 
provide some women with the intervention. In addition, some women who were 
enrolled did not receive the intervention package owing to inaccurate knowledge 
regarding use of the CBK and misoprostol. 
 
In conclusion, the present study found that provision of a CBK and misoprostol for 
self-administration was a feasible and highly acceptable intervention. Given the large 
number of unsupervised births and the high maternal mortality ratio recorded in 
PNG, the present study (despite some limitations) provided evidence for a 
community-based strategy and intervention that could provide a short-term solution 
to improve maternal health outcomes in this setting. 
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Figure 2 Supervision of births and CBK use among study participants. Abbreviation: 
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Box 1 Key messages communicated during community information sessions. 
Part 1: Normal process of safe childbirth 
• Childbirth can be dangerous 
• Planning for safe childbirth 
• Recognize the signs of labor 
• Help a woman when she is in labor 
• Recognize when the child is ready to be born 
• Care for the mother immediately after childbirth 
• Care of the mother and newborn from birth to 6 weeks 
• Plan for and space pregnancies 
 
Part 2: Danger signs in mothers and newborns 
• Know the danger signs and act quickly 
• Danger signs in labor 
• Danger signs in the mother after childbirth 
• Danger signs in the newborn 




Table 1 Location of birth and sociodemographic characteristics.a 







Birth location     NA 
Birthing house 19 (9.5) 19 (17.9) NA  
Bush or garden 3 (1.5) 3 (2.8) NA  
Riverside 15 (7.5) 15 (14.2) NA  
Roadside 3 (1.5) 3 (2.8) NA  
Coffee garden 7 (3.5) 7 (6.6) NA  
Garden house 3 (1.5) 3 (2.8) NA  
Own home  51 (25.5) 51 (48.1) NA  
Others home  1 (0.5) 1 (0.9) NA  
Other or missing data 4 (2.0) 4 (3.8) NA  
Health center 56 (28.0) NA 56 (59.6)  
Hospital  38 (19.0) NA 38 (40.4)  
Age, y     0.329 
<20 33 (16.5) 10 (9.4) 23 (24.5)  
20–24 65 (32.5) 38 (35.8) 27 (28.7)  
25–29 43 (21.5) 24 (22.6) 19 (20.2)  
30–34 40 (20.0) 25 (23.6) 15 (16.0)  
35–39 15 (7.5) 7 (6.6) 8 (8.5)  
≥40 4 (2.0) 2 (1.9) 2 (2.1)  
Marital status    0.037 
Not married 7 (3.5) 1 (0.9) 6 (6.4)  
Married 193 (96.5) 105 (99.1) 88 (93.6)  
Employment status    0.150 
Household duties and/or 
farmer 
192 (96.0) 104 (98.1) 88 (93.6)  
Employed or student 8 (4.0) 2 (1.9) 6 (6.4)  
Education level    0.017 
No formal education 84 (42.0) 49 (46.2) 35 (37.2)  
Year 1–6 78 (39.0) 45 (42.5) 33 (35.1)  
Year 7–12 31 (15.5) 12 (11.3) 19 (20.2)  
Tertiary level 5 (2.5) 0 5 (5.3)  
Unknown 2 (1.0) 0 2 (2.1)  
Religion    0.219 
Seventh-day Adventist 123 (61.5) 71 (67.0) 52 (55.3)  
Foursquare 42 (21.0) 20 (18.9) 22 (23.4)  
Other 35 (17.5) 15 (14.2) 20 (21.3)  
Abbreviation: NA, not applicable. 
a Values given as number (percentage) unless indicated otherwise. 
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Table 2 Obstetric and pregnancy history.a 







Parity    0.002 
0 52 (26.0) 18 (17.0) 34 (36.2)  
1 45 (22.5) 26 (24.5) 19 (20.2)  
2 35 (17.5) 21 (19.8) 14 (14.9)  
3 30 (15.0) 20 (18.9) 10 (10.6)  
4 28 (14.0) 15 (14.2) 13 (13.8)  
≥5 10 (5.0) 6 (5.7) 4 (4.3)  
Length of pregnancy at first 
prenatal care visit, wk 
   0.918 
<26 50 (25.0) 27 (25.5) 23 (24.5)  
26 up to 32 74 (37.0) 37 (34.9) 37 (39.4)  
>32 up to 36 52 (26.0) 30 (28.3) 22 (23.4)  
>36 24 (12.0) 12 (11.3) 12 (12.8)  
Total no. of prenatal care visits     0.583 
1 72 (36.0) 37 (34.9) 35 (37.2)  
2–3 99 (49.5) 56 (52.8) 43 (45.7)  
≥4 29 (14.5) 13 (12.3) 16 (17.0)  
Length of pregnancy at 
enrolment, wk 
   0.366 
≥26 to <32 103 (51.5) 52 (49.1) 51 (54.3)  
≥32 to <36 45 (22.5) 29 (27.4) 16 (17.0)  
≥36  52 (26.0) 25 (23.6) 27 (28.7)  
Birth outcome    0.131 
Live birth 198 (99.0) 106 (100.0) 92 (97.9)  
Stillbirth 2 (1.0) 0 2 (2.1)  
a Values given as number (percentage) unless indicated otherwise. 
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Table 3 Use and acceptability of the interventiona 







Used CBK     
No 85 (42.5)b 7 (6.6)b 78 (83.0)  
Yes 115 (57.5) 99 (93.4) 16 (17.0) <0.001 
Washing of hands 109 (94.8) 96 (97.0) 13 (81.3) <0.001 
Washing of hands with soap 109 (94.8) 97 (98.0) 12 (75.0) <0.001 
Using gloves at birth 115 (100.0) 99 (100.0) 16 (100.0) <0.001 
Using plastic sheet at birth 114 (99.1) 99 (100.0) 15 (93.8) <0.001 
Neonate delivered onto plastic sheet 115 (100.0) 99 (100.0) 16 (100.0) <0.001 
Using cord ties 107 (93.0) 99 (100.0) 8 (50.0) <0.001 
1 cord tie used 3 (2.8) 3 (3.0) 0  
2 cord ties used 104 (97.2) 96 (97.0) 8 (50.0)  
Using a scalpel blade to cut the cord 106 (92.1) 98 (99.0) 8 (50.0) <0.001 
Self-administered misoprostol 112 (97.4) 98 (99.0) 14 (87.5) <0.001 
Taken immediately after delivery 89 (79.5) 80 (81.6) 9 (64.3)  
Taken after expulsion of the placenta  18 (16.1) 15 (15.3) 3 (21.4)  
Taken after wash and/or rest  2 (1.8) 2 (2.0) 0  
Taken the next day 1 (0.9) 1 (1.0) 0  
Not specified when taken 2 (1.8) 0 2 (14.3)  
Acceptability of the intervention     
Would use CBK again     
Yes 111/115 (96.5) 99/99 (100.0) 12/16 (75.0) <0.001 
Missing data  4/115 (3.5) 0/99 4/16 (25.0)  
Would recommend CBK to others     
Yes 111/115 (96.5) 99/99 (100.0) 12/16 (75.0) <0.001 
Missing data 4/115 (3.5) 0/99 4/16 (25.0)  
Would take misoprostol again     
Yes 109/112 (97.3) 98/98 (100.0) 11/14 (78.6) <0.001 
Missing data  3/112 (2.7) 0/98 (0.0) 3/14 (21.4)  
Would recommend misoprostol to 
others 
    
Yes 109/112 (97.3) 98/98 (100.0) 11/14 (78.6) <0.001 
Missing data  3/112 (2.7) 0/98 3/14 (21.4)  
Abbreviation: CBK, clean birth kit. 
a Values given as number (percentage) or number/total number (percentage), unless indicated 
otherwise. 
b Includes 5 women who were not provided with a CBK at enrolment. 
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Table 4 Symptoms reported immediately after childbirth.a 









Any symptom 164 (82.0) 90 (80.4) 74 (84.1) 0.495 
Shivering  127 (63.5) 70 (62.5) 57 (64.8) 0.740 
Nausea 13 (6.5) 7 (6.3) 6 (6.8) 0.871 
Dizziness 30 (15.0) 14 (12.5) 16 (18.2) 0.264 
Fever 17 (8.5) 11 (9.8) 6 (6.8) 0.450 
Excessive bleeding b 48 (24.0) 15 (13.4) 33 (37.5) <0.001 
a Values are given as number (percentage) unless indicated otherwise. 
b Self-reported; >2 cups of blood. 
 
